Top Lung Cancer News of 2017

Slideshow

In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 23rd 2025
Article
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
August 23rd 2025
Podcast
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff
August 23rd 2025
Article
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
August 23rd 2025
Podcast
The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
August 23rd 2025
Article
A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
August 23rd 2025
Article